Researchers Coax Secrets, Possible Drug Targets From Multiple Myeloma Genome
This article was originally published in The Pink Sheet Daily
The whole genome study suggests new targets for the incurable bone-marrow cancer, but even the nearest at hand could be years away from producing a therapeutic agent.
You may also be interested in...
Bidding by multiple companies and strong data for a late-stage, targeted melanoma drug helped drive Daiichi Sankyo Company Limited's eye-popping $805 million acquisition of privately-held Plexxikon Inc.
As its melanoma drug advances in the clinic, Plexxikon obtains rights to co-promote it in the U.S.
Bolstered by a huge patient database, the Multiple Myeloma Research Consortium is helping to speed trials of new therapies, including some of the most talked about investigational drugs in the disease space, like carfilzomib and pomalidomide.